Stock SAVA CASSAVA SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Market Closed - Nasdaq
Other stock markets
 02:00:01 04/05/2024 am IST 		5-day change 1st Jan Change
22.05 USD -0.05% Intraday chart for Cassava Sciences, Inc. -1.30% -2.04%
29/04 North American Morning Briefing : Investors Brace -2- DJ
25/03 Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam MT

Evolution of the average Target Price on Cassava Sciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

08f7417c3d3078646710857.ltDC0wdzb9S0zSwH3OviZ4xJVSGB9oslcwxXeL5jh7Y.woCgsmQ6N5vEimtLlbmNBt8_Z2nip8oXIVgcT-gOzeChhaanaAEjmtqoaQ~e0f507c905c0f707a9014c1ba970aab4

Analyst Recommendations on Cassava Sciences, Inc.

B. Riley Cuts Cassava Sciences' PT to $28 From $44 on 'Uninterpretable' Open-Label Results of Simuflam in Alzheimer's Disease Patients; Keeps Neutral Rating MT
B. Riley Downgrades Cassava Sciences to Neutral From Buy, Notes Challenging Near-Term Catalyst Profile, Prolonged Litigation Mess; Maintains $44 PT MT
B. Riley Securities Lowers Cassava Sciences' Price Target to $44 from $58, Retains Buy Rating MT
B. Riley Lowers Cassava Sciences' Price Target to $58 from $72 to Factor in Increased Pace of Research & Development Expenses; Keeps Buy Rating MT
Univest Securities Starts Cassava Sciences at Sell With $8 Price Target, Says Phase 3 Trials Unlikely to Lead to Commercialization, Expects Further Stock Dilution MT
Maxim Group Adjusts Cassava Sciences Price Target to $110 From $190, Maintains Buy Rating MT
B. Riley Lowers Cassava Sciences' Price Target to $72 from $108 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
CASSAVA SCIENCES : B. Riley Lowers Cassava Sciences' PT to $108 from $145 on Investor Concerns Over Alleged Scientific Misconduct; Keeps Buy Rating MT
CASSAVA SCIENCES : B. Riley Raises Cassava Sciences' PT to $145 from $111 After Management Q&A on Simufilam, Keeps Buy Rating MT
CASSAVA SCIENCES : HC Wainwright Adjusts Cassava Sciences' Price Target to $124 From $97, Keeps Buy Rating MT
CASSAVA SCIENCES : Cantor Fitzgerald Downgrades Cassava Sciences to Neutral From Overweight, Adjusts PT to $100 From $73 MT
CASSAVA SCIENCES : B. Riley Raises Cassava Sciences' PT to $111 from $78 on Regulatory Tailwinds for Late-Stage AD Therapeutic, Keeps Buy Rating MT
CASSAVA SCIENCES : B. Riley Starts Cassava Sciences at Buy With $78 Price Target MT
CASSAVA SCIENCES : JonesTrading Initiates Cassava Sciences at Buy with $110 Price Target MT
CASSAVA SCIENCES : HC Wainwright & Co. Adjusts Price Target on Cassava Sciences, Inc to $97 From $66, Maintains Buy Rating MT
CASSAVA SCIENCES : Maxim Raises Cassava Sciences' Price Target to Street-High $80 from $14, Keeps Buy Rating MT
CASSAVA SCIENCES : HC Wainwright Adjusts Cassava Sciences' Price Target to $66 From $20, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
22.05 USD
Average target price
99.5 USD
Spread / Average Target
+351.25%
High Price Target
124 USD
Spread / Highest target
+462.36%
Low Price Target
75 USD
Spread / Lowest Target
+240.14%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cassava Sciences, Inc.

B. Riley
Univest Securities
Maxim
HC Wainwright
Cantor Fitzgerald
JonesTrading Institutional Services

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SAVA Stock
  4. Consensus Cassava Sciences, Inc.